Association between the valine/leucine247 polymorphism of β2-glycoprotein i and susceptibility to anti-phospholipid syndrome

A meta-analysis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: The objective of this paper is to explore whether the valine/leucine247 (Val/Leu247) polymorphism of β2-glycoprotein I (β2GPI) confers susceptibility to anti-phospholipid syndrome (APS) and thrombosis and predicts positivity for anti-β2GPI antibodies. Methods: A meta-analysis was conducted on the associations between the β2GPI Val/Leu247 polymorphism and susceptibility to APS and thrombosis and positivity for anti-β2GPI. Results: A total of 1507 patients with APS and 1450 controls in 12 comparative studies were included in this meta-analysis. Meta-analysis of the β2GPI Val/Leu247 polymorphism showed significant associations between the β2GPI Val allele and APS, thrombosis, and anti-β2GPI positivity (odds ratio (OR) 1.316, 95% confidence interval (CI) 1.068-1.621, p=0.010; OR 1.908, 95% CI 1.195-3.046, p=0.007; OR 1.630, 95% CI 1.018-2.609, p=0.042, respectively). A direct comparison between anti-β2GPI-positive and -negative patients revealed that the frequency of the Val allele was significantly higher in anti-β2GPI-positive patents (OR 1.514, 95% CI 1.017-1.253, p=0.041). Furthermore, a direct comparison between thrombosis-positive and -negative patients also indicated that the Val/Val+Val/Leu and the Val/Val vs. Leu/Leu genotypes of the β2GPI polymorphism were significantly elevated in patients with thrombosis (OR 2.817, 95% CI 1.200-6.610, p=0.017; OR 3.312, 95% CI 1.338-8.200, p=0.010, respectively). Conclusion: This meta-analysis shows that the β2GPI Val/Leu247 polymorphism is associated with susceptibility to APS and thrombosis and with anti-β2GPI positivity.

Original languageEnglish
Pages (from-to)865-871
Number of pages7
JournalLupus
Volume21
Issue number8
DOIs
Publication statusPublished - 2012 Jul 1

Fingerprint

Antiphospholipid Syndrome
Valine
Meta-Analysis
Glycoproteins
Thrombosis
Odds Ratio
Confidence Intervals
Patents
Gene Frequency
Alleles
Genotype

Keywords

  • β2-glycoprotein I
  • Anti-phospholipid syndrome
  • meta-analysis
  • polymorphism

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{6a5f04eff32d4ec7b027e0292b13df8f,
title = "Association between the valine/leucine247 polymorphism of β2-glycoprotein i and susceptibility to anti-phospholipid syndrome: A meta-analysis",
abstract = "Objective: The objective of this paper is to explore whether the valine/leucine247 (Val/Leu247) polymorphism of β2-glycoprotein I (β2GPI) confers susceptibility to anti-phospholipid syndrome (APS) and thrombosis and predicts positivity for anti-β2GPI antibodies. Methods: A meta-analysis was conducted on the associations between the β2GPI Val/Leu247 polymorphism and susceptibility to APS and thrombosis and positivity for anti-β2GPI. Results: A total of 1507 patients with APS and 1450 controls in 12 comparative studies were included in this meta-analysis. Meta-analysis of the β2GPI Val/Leu247 polymorphism showed significant associations between the β2GPI Val allele and APS, thrombosis, and anti-β2GPI positivity (odds ratio (OR) 1.316, 95{\%} confidence interval (CI) 1.068-1.621, p=0.010; OR 1.908, 95{\%} CI 1.195-3.046, p=0.007; OR 1.630, 95{\%} CI 1.018-2.609, p=0.042, respectively). A direct comparison between anti-β2GPI-positive and -negative patients revealed that the frequency of the Val allele was significantly higher in anti-β2GPI-positive patents (OR 1.514, 95{\%} CI 1.017-1.253, p=0.041). Furthermore, a direct comparison between thrombosis-positive and -negative patients also indicated that the Val/Val+Val/Leu and the Val/Val vs. Leu/Leu genotypes of the β2GPI polymorphism were significantly elevated in patients with thrombosis (OR 2.817, 95{\%} CI 1.200-6.610, p=0.017; OR 3.312, 95{\%} CI 1.338-8.200, p=0.010, respectively). Conclusion: This meta-analysis shows that the β2GPI Val/Leu247 polymorphism is associated with susceptibility to APS and thrombosis and with anti-β2GPI positivity.",
keywords = "β2-glycoprotein I, Anti-phospholipid syndrome, meta-analysis, polymorphism",
author = "Lee, {Young Ho} and Sungjae Choi and Ji, {Jong Dae} and Song, {Gwan Gyu}",
year = "2012",
month = "7",
day = "1",
doi = "10.1177/0961203312440348",
language = "English",
volume = "21",
pages = "865--871",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Association between the valine/leucine247 polymorphism of β2-glycoprotein i and susceptibility to anti-phospholipid syndrome

T2 - A meta-analysis

AU - Lee, Young Ho

AU - Choi, Sungjae

AU - Ji, Jong Dae

AU - Song, Gwan Gyu

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Objective: The objective of this paper is to explore whether the valine/leucine247 (Val/Leu247) polymorphism of β2-glycoprotein I (β2GPI) confers susceptibility to anti-phospholipid syndrome (APS) and thrombosis and predicts positivity for anti-β2GPI antibodies. Methods: A meta-analysis was conducted on the associations between the β2GPI Val/Leu247 polymorphism and susceptibility to APS and thrombosis and positivity for anti-β2GPI. Results: A total of 1507 patients with APS and 1450 controls in 12 comparative studies were included in this meta-analysis. Meta-analysis of the β2GPI Val/Leu247 polymorphism showed significant associations between the β2GPI Val allele and APS, thrombosis, and anti-β2GPI positivity (odds ratio (OR) 1.316, 95% confidence interval (CI) 1.068-1.621, p=0.010; OR 1.908, 95% CI 1.195-3.046, p=0.007; OR 1.630, 95% CI 1.018-2.609, p=0.042, respectively). A direct comparison between anti-β2GPI-positive and -negative patients revealed that the frequency of the Val allele was significantly higher in anti-β2GPI-positive patents (OR 1.514, 95% CI 1.017-1.253, p=0.041). Furthermore, a direct comparison between thrombosis-positive and -negative patients also indicated that the Val/Val+Val/Leu and the Val/Val vs. Leu/Leu genotypes of the β2GPI polymorphism were significantly elevated in patients with thrombosis (OR 2.817, 95% CI 1.200-6.610, p=0.017; OR 3.312, 95% CI 1.338-8.200, p=0.010, respectively). Conclusion: This meta-analysis shows that the β2GPI Val/Leu247 polymorphism is associated with susceptibility to APS and thrombosis and with anti-β2GPI positivity.

AB - Objective: The objective of this paper is to explore whether the valine/leucine247 (Val/Leu247) polymorphism of β2-glycoprotein I (β2GPI) confers susceptibility to anti-phospholipid syndrome (APS) and thrombosis and predicts positivity for anti-β2GPI antibodies. Methods: A meta-analysis was conducted on the associations between the β2GPI Val/Leu247 polymorphism and susceptibility to APS and thrombosis and positivity for anti-β2GPI. Results: A total of 1507 patients with APS and 1450 controls in 12 comparative studies were included in this meta-analysis. Meta-analysis of the β2GPI Val/Leu247 polymorphism showed significant associations between the β2GPI Val allele and APS, thrombosis, and anti-β2GPI positivity (odds ratio (OR) 1.316, 95% confidence interval (CI) 1.068-1.621, p=0.010; OR 1.908, 95% CI 1.195-3.046, p=0.007; OR 1.630, 95% CI 1.018-2.609, p=0.042, respectively). A direct comparison between anti-β2GPI-positive and -negative patients revealed that the frequency of the Val allele was significantly higher in anti-β2GPI-positive patents (OR 1.514, 95% CI 1.017-1.253, p=0.041). Furthermore, a direct comparison between thrombosis-positive and -negative patients also indicated that the Val/Val+Val/Leu and the Val/Val vs. Leu/Leu genotypes of the β2GPI polymorphism were significantly elevated in patients with thrombosis (OR 2.817, 95% CI 1.200-6.610, p=0.017; OR 3.312, 95% CI 1.338-8.200, p=0.010, respectively). Conclusion: This meta-analysis shows that the β2GPI Val/Leu247 polymorphism is associated with susceptibility to APS and thrombosis and with anti-β2GPI positivity.

KW - β2-glycoprotein I

KW - Anti-phospholipid syndrome

KW - meta-analysis

KW - polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84861816626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861816626&partnerID=8YFLogxK

U2 - 10.1177/0961203312440348

DO - 10.1177/0961203312440348

M3 - Article

VL - 21

SP - 865

EP - 871

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 8

ER -